Innovative AI-driven technologies continue to push diagnostics forward, with Wholomics unveiling metabolomic platforms capable of detecting multiple cancers by analyzing serum metabolic and lipidomic signatures rather than tumor DNA. Early data cover a wide cancer spectrum including pancreatic and colorectal cancers. Concurrently, UK startup OutSee has launched Nomaly, a computational tool predicting phenotypic outcomes from genomic variants with potential in target identification, leveraging machine learning to interpret rare genetic effects. These advances show promise in enhancing early cancer detection and uncovering disease mechanisms through integrative bioinformatics.